BioCentury | Oct 5, 2020
Deals

Bristol Myers adds CV therapy through $13.1B MyoKardia takeout

...II testing: cimlanod, a second-generation prodrug of nitroxyl for heart failure; and BMS-986177 (JNJ-70033093), a Factor XIa...
BioCentury | Jul 8, 2020
Finance

VarmX attracts investor syndicate with financial reserves to support coagulation company beyond €32M series B

...other anticoagulation reversal or bypassing agents. The next most advanced program targets Factor XIa; the leading Factor XIa...
BioCentury | Mar 1, 2019
Financial News

Blackstone, Novartis spin out cardiovascular newco Anthos

...an undisclosed minority stake in the company. MAA868 is an inhibitor of Factor XI and Factor XIa...
BioCentury | Feb 27, 2019
Company News

Blackstone, Novartis spin out cardiovascular newco Anthos

...an undisclosed minority stake in the company. MAA868 is an inhibitor of Factor XI and Factor XIa...
BioCentury | Apr 20, 2018
Company News

BMS, JNJ in deal for Factor XIa inhibitor

...the Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) partnered to develop and commercialize Factor XIa...
...York, N.Y. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Neurology Chris Lieu Bristol-Myers Squibb Co. Johnson & Johnson Factor XIa Stroke BMS-986177...
BioCentury | Apr 16, 2018
Company News

BMS, JNJ in deal for Factor XIa inhibitor

...the Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) partnered to develop and commercialize Factor XIa...
...partners plan to begin Phase II testing of BMS-986177 to prevent secondary stroke. Chris Lieu Johnson & Johnson Factor XIa Stroke BMS-986177...
BioCentury | Nov 30, 2017
Clinical News

eXIthera reports Phase I data for thrombosis candidate

...in 2H18. eXIthera Pharmaceuticals Inc., Westborough, Mass. Product: EP-7041 Business: Cardiovascular Molecular target: Factor XIa Description: Factor XIa...
...clotting biomarker measurements Status: Phase I data Milestone: Start Phase II (2H18) Elizabeth S. Eaton eXIthera Pharmaceuticals Inc. Factor XIa EP-7041...
BioCentury | Aug 28, 2017
Clinical News

Xarelto lowers CV risk, ups major bleeds in artery disease

...direct Factor Xa inhibitor. Last year, researchers at Pfizer Inc. (NYSE:PFE) identified a preclinical anti- Factor XIa...
BioCentury | Mar 8, 2017
Translation in Brief

Up to eleven

...vessel walls, creating new value for the target. Factor XI is the proenzyme precursor to Factor XIa...
...But Factor Xa inhibition comes with higher bleeding risk than blockade of Factor XI or Factor XIa...
...patients with certain co-morbidities. At least three companies are developing agents targeting Factor XI or Factor XIa...
BioCentury | Sep 29, 2016
Product R&D

Safety Factor

...site, and because the company has already made a tailored reversal agent. Factor Xa and Factor XIa...
...so far," said Jeffrey Weitz, "I think overall a strategy that targets Factor XI or Factor XIa...
...Product Profile INNOVATION STAGE Product Factor XIa-blocking mAb, plus antidote reversal agent for safety Concept Blocking Factor XIa...
Items per page:
1 - 10 of 21